Core Insights - Eton Pharmaceuticals has acquired Galzin® (zinc acetate), a medication for Wilson Disease, enhancing its portfolio in rare disease treatments [1][2][7] - The acquisition aligns with Eton's mission to support life-saving treatments for ultra-rare patient populations [2] Company Overview - Eton Pharmaceuticals is focused on developing and commercializing treatments for rare diseases, currently offering six commercial products and four additional candidates in late-stage development [12] Product Details - Galzin is FDA-approved for maintenance treatment of Wilson Disease patients who have been initially treated with a chelating agent, with an estimated patient population of less than 5,000 in the U.S. [3][4] - Eton plans to commercialize Galzin in the U.S. in Q1 2025, supported by its metabolic sales force and the Eton Cares patient support program [4] Patient Support Program - The Eton Cares program will provide a $0 co-pay for qualified commercial patients, prescription fulfillment, insurance benefits investigation, and educational support [4] European Rights - Eton has acquired European rights to Galzin, where it is marketed as Wilzin® by a third party, with Eton continuing to supply the product under an existing distribution agreement [5]

Core Insights - Eton Pharmaceuticals has completed the acquisition of Increlex® (mecasermin injection) from Ipsen S.A., enhancing its portfolio in pediatric endocrinology [1][16] - Increlex® is the only FDA and EMA approved treatment for severe primary insulin-like growth factor 1 deficiency (SPIGFD) in pediatric patients aged 2 years and older [2][25] - The product is now available in the U.S. through AnovoRx, a specialty pharmacy, which will also manage the Eton Cares Program to assist patients [17][16] Group 1: Acquisition Details - The acquisition was financed using Eton's cash reserves and an expansion of its existing credit facility with SWK Holdings [3] - Ipsen will continue to distribute Increlex® outside the U.S. for a six-month transition period before Eton takes over commercialization [3] Group 2: Product Information - Increlex® is approved in 41 territories, including the U.S. and EU, with an estimated 200 patients in the U.S. and 900-1,000 in Europe suffering from SPIGFD [2] - The product is indicated for growth failure in pediatric patients with severe primary IGF-1 deficiency, defined by specific height and IGF-1 level criteria [25][26] Group 3: Patient Support and Accessibility - The Eton Cares Program will provide prescription fulfillment, insurance benefits investigation, educational support, and financial assistance for qualifying patients [17] - Co-pay assistance will be available to allow for $0 co-pays for eligible patients [17]

Core Insights - Eton Pharmaceuticals announced positive results from a clinical trial of PKU GOLIKE, a protein substitute for treating phenylketonuria (PKU), showing improved metabolic control during prolonged fasting periods [1][5]. Clinical Trial Details - The study was a randomized, crossover, controlled trial conducted on pediatric patients with classical PKU at Birmingham Children's Hospital, UK, comparing PKU GOLIKE to standard amino acid substitutes [3]. - Results indicated a statistically significant reduction in blood phenylalanine (Phe) levels by an average of 17.8% and an increase in blood tyrosine (Tyr) levels by an average of 33.8% in the PKU GOLIKE group compared to standard substitutes [4]. Clinical Significance - The principal investigator highlighted that administering PKU GOLIKE as the final daily dose led to better metabolic control in patients, confirming its prolonged-release profile's effectiveness [5]. - The findings are expected to support the adoption of PKU GOLIKE among healthcare providers and the PKU community [5]. Product Information - PKU GOLIKE is a food for special medical purposes designed for dietary management of PKU, utilizing a proprietary drug delivery platform that mimics natural protein absorption [12]. - The product line includes various forms, such as flavorless granules and medical formula bars, and has been commercially available in the U.S. since October 2022 [12]. Future Presentation - The study findings will be presented at the 2025 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Los Angeles [6].

Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness sector, including significant experience in the pediatric endocrinology specialty. DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, ...

Amglidia® has been approved by the European Medicines Agency (EMA) and is commercially available in EuropeStrong strategic fit with Eton’s existing pediatric endocrinology focusAmglidia has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA)Potential New Drug Application (NDA) submission in 2026 DEER PARK, Ill., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and c ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants David Krempa – Chief Business Officer Sean Brynjelsen – Chief Executive Officer James Gruber – Chief Financial Officer Conference Call Participants Chase Knickerbocker – Craig-Hallum Operator Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode. Following the formal remarks, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 | --- | --- | --- | |------------------------------------ ...

Exhibit 99.1 Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results ● Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million or $0.02 per diluted share ● Entered into an asset purchase agreement to acquire Increlex® (mecasermin injection) ● Q3 2024 product sales increased 40% over Q3 2023, representing 15th straight quarter of sequential product sales growth ● Produced positive quarterly GAAP net income from product sales for first time in company history ● Generated cash fro ...

Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted shareEntered into an asset purchase agreement to acquire Increlex® (mecasermin injection)Q3 2024 product sales increased 40% over Q3 2023, representing 15th straight quarter of sequential product sales growthProduced positive quarterly GAAP net income from product sales for first time in company historyGenerated cash from operations of $2.9 million in Q3 2024Granted additional patent for ET-400Management to hol ...